Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, announced that Nello Mainolfi, PhD, Co-Founder, President and CEO, will participate in Fireside Chats at the following upcoming investor conferences:
Presentation webcasts will be available under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com. Archived webcast replays will be available on the website for approximately 90 days.
About Kymera Therapeutics
Kymera is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics. Kymera’s Pegasus platform is a powerful drug discovery engine, advancing novel small molecule therapies candidates designed to harness the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. With a focus on undrugged nodes in validated pathways, Kymera is advancing a pipeline of novel therapeutic candidates designed to address the most intractable of pathways and provide new treatments for patients. Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat patients with a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. For more information, visit www.kymeratx.com.
Investor Contact:
Bruce Jacobs
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
857-285-5300
Chris Brinzey
Managing Director, Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
339-970-2843
Media Contact:
Todd Cooper
Senior Vice President, Corporate Affairs
This email address is being protected from spambots. You need JavaScript enabled to view it.
857-285-5300
Last Trade: | US$59.89 |
Daily Change: | 2.68 4.68 |
Daily Volume: | 805,437 |
Market Cap: | US$4.280B |
August 11, 2025 June 25, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load